It reviews brain-imaging evidence for a neural mechanism, not symptom outcomes, so it cannot confirm or rule out clinical benefit.What exactly did the researchers study?They systematically reviewed 12 human neuroimaging studies that compared CBD with placebo using fMRI, PET, or SPECT under stress or anxiety conditions.What was the main finding?Reported brain activation and perfusion changes were scattered across many regions with mixed directions of effect, showing no consistent, reproducible pattern across studies.How strong is this evidence?The review itself is methodologically rigorous and PROSPERO-registered, but the underlying studies were rated as having some concerns or high risk of bias, with low to very low GRADE certainty.Why does risk of bias matter here?Risk of bias affects how confidently a reader can attribute a reported brain change to CBD itself rather than to small samples, design choices, or chance.Does this apply to every CBD product?No
However, Ozempic's effect on gastric emptying and potential gastrointestinal side effects warrant consideration
It is not appropriate for individuals with a history of certain cancers, particularly hormone-sensitive tumors
European Medicines Agency ) Kapcsold: Cmlapfot: Wikimedia Commons/Mr Hyde at Czech Wikipedia
Eli Lilly and Company announced results from a late-stage clinical trial showing that its next-generation obesity treatment retatrutide delivered unprecedented weight-loss outcomes, outperforming its existing blockbuster drug Zepbound (tirzepatide)
Safety and validation of the method
